Scarica l'app Stockscreener
877.62
3.50%
-31.87
Dopo l'orario di chiusura:
875.00
-2.62
-0.30%
Argen X Se Adr Borsa (ARGX) Ultime notizie
VCRE|Vicore Pharma Holding AB ADR|Price:13.780|Chg%:-0.135 - TradingKey
RBC Capital Adjusts argenx SE ADR Price Target to $945 From $890, Maintains Outperform Rating - marketscreener.com
Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This Profitable Autoimmune Biotech Trades Near A High And A Buy Point - Investor's Business Daily
Argenx, stock of the day, eyes buy point amid triple-digit growth - MSN
Argenx Fends Off First-Quarter Seasonality, But Shares Defy Analysts' Bullish Views - Investor's Business Daily
Argenx stock holds the focus on its global immunology franchise. - ad-hoc-news.de
Vicore Pharma Holding AB ADR (VCRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ARGXArgen X SE ADR Options - Finviz
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx stock hits all-time high at 934.69 USD - Investing.com
ARGX Stock Price, Quote & Chart - ChartMill
BofA raises argenx stock price target to $1,088 on myositis data - Investing.com South Africa
Argenx, Stock Of The Day, Eyes Buy Point Amid Triple-Digit Growth - Investor's Business Daily
A2H9WD Forecast — Price Target — Prediction for 2027 - TradingView
European ADRs Climb In Thursday U.S. Morning Session: ARGX, PHIA, CRTO In Focus - foreignpolicyjournal.com
argenx SE Sponsored ADR Actuals & Estimates (NASDAQ:ARGX) - TradingView
H.C. Wainwright reiterates argenx stock rating on myositis trial update By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates argenx stock rating on myositis trial update - Investing.com
Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy? - Investor's Business Daily
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity By Investing.com - Investing.com South Africa
TD Cowen reiterates Buy on argenx stock, cites IMNM opportunity - Investing.com
RBC Capital reiterates argenx stock Outperform on myositis data - Investing.com
RBC Capital reiterates argenx stock Outperform on myositis data By Investing.com - Investing.com Australia
Argenx stock price target held at $1,014 by Oppenheimer on myositis strategy - Investing.com Nigeria
Argenx stock falls after myositis drug trial update - Investing.com
Biotech breakout: iShares Biotechnology ETF hits all-time high - MSN
Form 6K argenx NV ADR For: 23 June - Investing.com UK
Form 6K argenx NV ADR For: 23 June By Investing.com - Investing.com Nigeria
argenx to Host Autoimmune Myositis R&D Webinar - GlobeNewswire Inc.
Novabridge Biosciences ADR (NBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galapagos ADR Representing Ord Shs (LKFT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Argenx SE Stock (NL0010832176): Analyst price target move puts biotech in focus - AD HOC NEWS
European ADRs Rose In US Trading As Biotech Led - Finimize
European Equities Traded in US as ADRs Rise in Thursday Trading - Moomoo
Sanofi Scraps Its Argenx Rival; Why Another Biotech Took The Hit - Investor's Business Daily
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know - TradingView
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
William O'Neil Initiates Argenx at Buy - Moomoo
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference - Barchart.com
4.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):